Top in rheumatology: Osteoarthritis treatment; COVID-19’s impact on rheumatic diseases
Click Here to Manage Email Alerts
With the continued absence of reliable disease-modifying treatments for osteoarthritis, health care providers continue to encourage patients to focus on exercise and wellness.
“Behavioral changes, including diet and exercise, continue to be first-line treatment for knee OA,” Abigail Gilbert, MD, an assistant professor of medicine in the division of rheumatology, allergy and immunology at the University of North Carolina Chapel Hill, told Healio.
It was the top story in rheumatology last week.
Another top story was about the impact of COVID-19 on patients with autoimmune and inflammatory diseases. Cassandra Calabrese, DO, of the department of rheumatology and immunologic disease at the Cleveland Clinic, said that rheumatologists should be able to educate patients regarding the availability of preventive and therapeutic options.
Read these and more top stories in rheumatology below:
‘Pain is normal’: The frustrating present and possible future of osteoarthritis treatment
When it comes to patients with osteoarthritis adopting, much less maintaining, an exercise regimen to improve their condition, most rheumatologists have just one thought: “Easier said than done.” Read more.
COVID-19 pandemic ‘still with us’ for patients with autoimmune, inflammatory diseases
Although omicron variants appear generally less severe and more manageable than previous SARS-CoV-2 strains, patients with rheumatologic conditions should remain vigilant, according to a presenter. Read more.
FDA approves sarilumab as first biologic to treat polymyalgia rheumatica
The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an inadequate response to, or cannot taper, corticosteroids, according to a press release from Sanofi. Read more.
'Now everyone's an immunologist': How COVID-19 helps improve understanding of immunology
The study of COVID-19 may in turn improve the understanding of immunology by demonstrating that the immune system is “highly alive,” said a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium. Read more.
CAR T-cell therapy, new drugs ushering in ‘lupus renaissance’
Several new drugs and promising therapies, including chimeric antigen receptor T-cell therapy, have ushered in a “lupus renaissance,” said a speaker. Read more.